High-density lipoprotein: a novel target for antirestenosis therapy

Clin Transl Sci. 2014 Dec;7(6):500-11. doi: 10.1111/cts.12186. Epub 2014 Jul 15.

Abstract

Restenosis is an integral pathological process central to the recurrent vessel narrowing after interventional procedures. Although the mechanisms for restenosis are diverse in different pathological conditions, endothelial dysfunction, inflammation, vascular smooth muscle cell (SMC) proliferation, and myofibroblasts transition have been thought to play crucial role in the development of restenosis. Indeed, there is an inverse relationship between high-density lipoprotein (HDL) levels and risk for coronary heart disease (CHD). However, relatively studies on the direct assessment of HDL effect on restenosis are limited. In addition to involvement in the cholesterol reverse transport, many vascular protective effects of HDL, including protection of endothelium, antiinflammation, antithrombus actions, inhibition of SMC proliferation, and regulation by adventitial effects may contribute to the inhibition of restenosis, though the exact relationships between HDL and restenosis remain to be elucidated. This review summarizes the vascular protective effects of HDL, emphasizing the potential role of HDL in intimal hyperplasia and vascular remodeling, which may provide novel prophylactic and therapeutic strategies for antirestenosis.

Keywords: high-density lipoprotein; intimal hyperplasia; restenosis; vascular remodeling.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Coronary Restenosis / physiopathology
  • Coronary Restenosis / therapy*
  • Humans
  • Lipoproteins, HDL / metabolism*
  • Molecular Targeted Therapy*
  • Receptors, Lipoprotein / metabolism

Substances

  • Lipoproteins, HDL
  • Receptors, Lipoprotein
  • high density lipoprotein receptors